Report Highlights
The global market for head and neck cancer therapeutics is estimated to increase from $1.7 billion in 2022 to $2.6 billion by 2027, at a compound annual growth rate (CAGR) of 8.5% from 2022 through 2027.
Report Includes
- 64 data tables and 17 additional tables
- A comprehensive overview of the global markets for head and neck cancer therapeutics within the industry
- Analyses of the global market trends, with historic market revenue data for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Estimation and forecast the actual market size for head and neck cancer therapeutics, and corresponding market share analysis by diagnostic method, treatment type, disease indication, route of administration, therapeutic class, end-user, and region
- Assessment of major driving factors, opportunities and challenges in this innovation driven market, with emphasis on COVID-19 impact on the head and neck cancer therapeutics market
- Discussion of the industry value chain analysis providing a systematic study of key intermediaries involved, with emphasis on new products development, regulatory scenario, and reimbursement and pricing factors
- In-depth information on increasing investments on R&D activities, key technology issues, industry specific challenges, and major types of end-user markets
- Market share analysis of the key market participants in the global pharmaceuticals industry, their research priorities, product portfolios, pipeline products, and company competitive landscape
- Descriptive company profiles of the leading global players, including AstraZeneca plc, Bristol-Myers Squibb, Eli Lilly and Co., Sanofi S.A., Merck & Co., and Pfizer Inc.
Report Scope
This report aims to provide a comprehensive study of the global market for head and neck cancer therapeutics, both in terms of quantitative and qualitative data, to help businesses develop growth strategies, assess the market landscape, analyze their positions in the current marketplace, and make informed business decisions regarding head and neck cancer therapeutic drugs.
An in-depth analysis of the global head and neck cancer therapeutics market includes historical data and market projections on sales by type of diagnostic method, treatment type, disease indication, route of administration, therapeutic class, and end user. It describes the different types of head and neck cancers (lip and oral cavity cancer, laryngeal cancer, oropharyngeal cancer, salivary gland cancer, nasopharyngeal cancer, and hypopharyngeal cancer) and their current and historical market revenues. This report also categorizes the global head and neck cancer therapeutics market based on the route of administration (injectable and oral).
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market shares. The report also discusses pipeline analysis and the new regulatory landscape of the drugs marketed.
Report Synopsis
| Report Metrics | Details | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2021 | ||||||||||
| Forecast period considered | 2022-2027 | ||||||||||
| Base year market size | $1.6 billion | ||||||||||
| Market size forecast | $2.5 billion | ||||||||||
| Growth rate | CAGR of 8.5% from 2022 to 2027 | ||||||||||
| Units considered | $ Millions | ||||||||||
| Segments covered | Diagnostic Method, Treatment Type, Disease Indication, Route of Administration, Therapeutic Class, End User | ||||||||||
| Regions covered | North America, Europe, Asia-Pacific, Rest of the World (RoW) | ||||||||||
| Countries covered | United States, Canada, Germany, France, U.K., Spain, Italy, Sweden, Switzerland, Denmark, Norway, Poland, Belgium, Austria, Netherlands, Russia, Japan, China, India, Australia, South Korea, Singapore, New Zealand, Taiwan, Malaysia, Thailand, Philippines, Indonesia, Latin America, Middle East and Africa | ||||||||||
| Key Market Drivers |
|
||||||||||
| Companies studied |
|
||||||||||
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
- Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets (HLC176E)
- Carbon Credits Market: Global Outlook (EGY200A)
- Drugs and Diagnostics for Hematological Disorders: Global Markets (PHM116C)
- Global Flame and Smoke Detectors Markets (MFG092A)
- Biodegradable Polymers: Global Markets and Technologies (PLS025K)
Related Reports
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.
Melanoma Therapeutics: Global Markets
The global market for melanoma therapeutics is estimated to increase from $7.4 billion in 2023 to reach $12.1 billion by 2028, at a compound annual growth rate (CAGR) of 10.2% from 2023 through 2028.
Monoclonal Antibodies for Oncology: Global Markets
The global market for monoclonal antibodies in oncology is estimated to grow from $76.2 billion in 2022 to more than $138.1 billion by 2027, with a compound annual growth rate (CAGR) of 12.6% during the forecast period of 2022-2027.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics anddevice technologies should grow from $391.8 billion in 2021 to $553.0 billion by 2026, at compound annual growth rate (CAGR) of 7.1% for the period of 2021-2026.
Recent Reports
Drugs and Diagnostics for Hematological Disorders: Global Markets
The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.
Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets
The global market for gastrointestinal (GI) therapeutics and diagnostics is expected to grow from $86.0 billion in 2023 and projected to reach $122.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2023 to 2028.
Global Markets and Technologies for Advanced Drug Delivery Systems
The global market for advanced drug delivery systems is expected to increase from $262.6 billion in 2023 to $359.1 billion by the end of 2028, with a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2028.
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.
Chagas Disease: American trypanosomiasis Market
The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More